Novavax’s Nuvaxovid (NVX-CoV2373) Booster Dose Receives the MHRA Recommendation for Expanded Conditional Marketing Authorization to Prevent COVID-19
Shots:
- The CMA for Nuvaxovid has been expanded by the MHRA as a homologous & heterologous booster dose following the primary 2-dose vaccination series of Nuvaxovid or an mRNA or adenoviral vector vaccine for COVID-19 in adults aged ≥18yrs.
- The decision was based on the P-II trial across the US & Australia, the P-II trial across South Africa & UK-sponsored (COV-BOOST) trial which demonstrated that 3rd dose increased immune responses against an ancestral strain of SARS-CoV-2 & exceeding levels that were protective in P-III clinical trials
- In the (COV-BOOST) trial, Nuvaxovid as a 3rd heterologous booster dose increased Ab titers. In the Novavax-sponsored trials, local and systemic reactions had a median duration of ~2 days & reactogenicity events showed an increased incidence
Ref: Novavax | Image: Novavax
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
